SCHEMBL13856437

SCHEMBL13856437

Cc1cc(O)cc2oc(-c3cc(O)c(O)c(O)c3)c(O)c(=O)c12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.76
KMT2A Q03164 7/20 0.76
CYP1A2 P05177 7/20 0.76
CYP1A1 P04798 6/20 0.76
CYP1B1 Q16678 6/20 0.76
CYP3A4 P08684 5/20 0.76
CYP2C9 P11712 5/20 0.76
FTO Q9C0B1 5/20 0.76
ABCC1 P33527 4/20 0.76
TDP1 Q9NUW8 4/20 0.76
KDM4E B2RXH2 4/20 0.76
ALOX15 P16050 4/20 0.76
RECQL P46063 4/20 0.76
HIF1A Q16665 4/20 0.76
HSD17B10 Q99714 4/20 0.76
BCHE P06276 4/20 0.76
CYP2D6 P10635 4/20 0.76
MAPT P10636 4/20 0.76
ACHE P22303 4/20 0.76
CYP2C19 P33261 4/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13856525 0.87 MEN1 (0.78) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Myricetin SCHEMBL19302 0.86 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Myricetin SCHEMBL29357150 0.86 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Myricetin SCHEMBL3503992 0.86 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL7929171 0.86 MEN1 (0.81) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL13620318 0.85 MEN1 (0.74) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL15197351 0.82 MEN1 (0.81) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL19236381 0.82 MEN1 (0.76) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL12640011 0.82 NOX4 (0.79) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL1883826 0.81 MAPK8 (0.77) MEN1KMT2ACYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124627-A1 COMPOSITIONS FOR SLEEPING DISORDERS CHAN HSIAO CHANG 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124627-A1 COMPOSITIONS FOR SLEEPING DISORDERS PER2, CRY1, CRY2 MEN1 4015/4885KMT2A 353/4885CYP1A2 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.